UiO/OUS/Ahus-based NO-Age/AD is determined to move their original pre-clinical discoveries into clinical trials aiming to understand mechanisms of ageing and diseases in humans and to develop safe and effective treatments to diseases. Their final aim is to promote happy, productive, and enjoyable lives to humans, especially to the old population as well as young people suffering with premature ageing diseases.
Some of their clinical trials are (were):
1. NAD-AT
NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia (Leader: Prof. Hilde Nilsen; participant Prof. Dr. Evandro Fang).
Study Details | NCT04870866 | NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia | ClinicalTrials.gov
Publications (continually updated):
Long-Term Nicotinamide Riboside Use Improves Coordination and Eye Movements in Ataxia Telangiectasia – PubMed
2. NARNIA
Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients (NARNIA) (co-leaders Prof. Dr. Torbjorn Omland and Prof. Dr. Evandro Fang; Prof. Hilde Nilsen was the initiator and a participant).
Study Details | NCT05732051 | Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients | ClinicalTrials.gov
3. Mito-AD
Phase II clinical trial on the effect of urolithin A in Alzheimer’s disease. Evandro Fei Fang, Ph.D., Akershus University Hospital, Oslo, Norway (Martin Vyhnálek, M.D., Ph.D., Co-investigator, Second Faculty of Medicine, Charles University, Prague, Czech Republic).
NO-AD 